EVOLUS, INC. Notes Payable, Fair Value Disclosure
EVOLUS, INC. (EOLS) had Notes Payable, Fair Value Disclosure of $19.28 million as of 2020-12-31, per its 10-K filed 2022-03-03.
Discontinued › Notes › Fair Value Disclosures
us-gaap:NotesPayableFairValueDisclosure · last filed 2022-03-03
- 2020-12-31: Notes Payable, Fair Value Disclosure $19.28M.
| Period end | Notes Payable, Fair Value Disclosure |
|---|---|
| 2020-12-31 | $19.28M 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |